OT-12

OT-12 is a peripherally restricted, long-acting oxytocin receptor (OTR) agonist developed for the treatment of obesity and associated metabolic disorders. It is a peptide analog of oxytocin that has been engineered through conjugation with fatty acid moieties, a modification that enhances its binding affinity to serum albumin and significantly extends its half-life to approximately 24 hours (demonstrated in mouse models). Unlike native oxytocin, OT-12 is designed to be periphery-restricted with minimal brain exposure, thereby targeting peripheral oxytocinergic pathways to reduce food intake and promote weight loss while minimizing potential central nervous system-mediated side effects. In preclinical models of diet-induced obesity, OT-12 demonstrated more potent anorexigenic and body-weight-reducing effects than carbetocin when administered subcutaneously.

Other names

oxytocin analog OT-12fatty-acid conjugated oxytocin agonist